GlassScriptPhysician profile
Jason Arthur Barr
NPI 1457312027
$3,106.42
in general payments reported to CMS, 2019-2025
23 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $82.28 · 2022: $93.69 · 2023: $406 · 2024: $955 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,069 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.36 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,228.16 | 2019-2025 | Skyrizi, Humira |
| Genzyme Corporation | $338.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $319.24 | 2024-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $308.79 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $151.02 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $141.83 | 2019-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.68 | 2019-2025 | Jublia |
| Leo Pharma INC. | $93.73 | 2025 | Anzupgo, Adbry |
| Ucb, INC. | $74.43 | 2019-2025 | Bimzelx |
| Amgen INC. | $61.99 | 2024-2025 | Otezla, Otezla |
| Biowound Solutions, INC. | $39.34 | 2025 | Bio-Connekt |
| Novartis Pharmaceuticals Corporation | $31.24 | 2025 | |
| Kyowa Kirin, INC. | $25.56 | 2023 | Poteligeo |
| Krystal Biotech INC | $25.23 | 2024 | Vyjuvek |
| Almirall LLC | $22.67 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $22.38 | 2025 | Opzelura |
| Organogenesis INC. | $18.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.65 | 2023 | Sotyktu |
| Merck Sharp & Dohme LLC | $15.68 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.19 | 2024 | Zoryve |
| Celltrion USA INC. | $14.46 | 2025 | Vegzelma |
| Pfizer INC. | $13.96 | 2019 | |
| Advanced Oxygen Therapy INC. | $8.60 | 2024 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.